<DOC>
	<DOCNO>NCT00031941</DOCNO>
	<brief_summary>RATIONALE : CC-5013 may stop growth cancer stop blood flow tumor . PURPOSE : Phase I trial study effectiveness CC-5013 treating patient solid tumor and/or lymphoma respond previous therapy .</brief_summary>
	<brief_title>CC-5013 Treating Patients With Cancer That Has Not Responded Previous Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose CC-5013 patient refractory solid tumor and/or lymphoma . - Characterize pharmacokinetic profile drug patient . - Determine whether correlation make plasma concentration drug toxicity clinical activity biological activity patient . - Characterize side effect profile drug patient . - Determine dose-limiting toxicity drug patient . OUTLINE : This dose-escalation study . Patients receive oral CC-5013 day 1 . Within 4-10 day , patient begin second course receive oral CC-5013 daily day 1-21 . Subsequent course repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos CC-5013 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 6 patient experience dose-limiting toxicity . Patients follow 2 week . PROJECTED ACCRUAL : A total 3-51 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm refractory solid tumor and/or lymphoma No brain metastases primary CNS malignancy PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : More 3 month Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal ALT AST less 2.5 time normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No unstable newly diagnose angina pectoris No myocardial infarction within past 6 month No New York Heart Association class II , III , IV congestive heart failure Pulmonary : No chronic obstructive lung disease require oxygen therapy Other : No uncontrolled seizures No concurrent acute critical illness No serious untreated infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas , mitomycin , carboplatin ) No concurrent cytotoxic chemotherapy Endocrine therapy : At least 4 week since prior hormonal therapy Concurrent luteinizing hormonereleasing hormone agonist require patient prostate cancer unless prior orchiectomy perform Radiotherapy : At least 4 week since prior radiotherapy Surgery : See Endocrine therapy Prior surgery allow Other : Recovered prior therapy No concurrent anticonvulsant ( e.g. , phenobarbital , phenytoin , carbamazepine ) No concurrent rifampin No concurrent grapefruit juice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>small intestine lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>